This morning, PropThink featured an update on Ventrus Biosciences (NASDAQ: VTUS) post its second quarter results, noting that the company has enough cash to get to its next value-creating milestones (see our analysis from this morning). A meeting with FDA next month may be a reason that investors come back to the name after the company’s drug candidate for hemorrhoids failed to show a benefit in Phase III trials, despite strong results for VTUS’ other Phase III drug candidate, VEN-307, for anal fissures.
PropThink mentioned that an analyst at Cantor Fitgerald was negative on the stock after the hemorrhoids event, however, upgraded Ventrus Biosciences from a ‘hold’ to a ‘buy’ shortly after our coverage of the company this morning. The consensus among all analysts is that the stock is now attractively valued. Expect VTUS to continue to rise into the September meeting between the company and the FDA regarding the regulatory filing for VEN-307.